著者

Shigeru Makita Takanori Yasu Yoshihiro J Akashi Hitoshi Adachi Hideo Izawa Shunichi Ishihara Yoshitaka Iso Hideo Ohuchi Kazuto Omiya Yusuke Ohya Koichi Okita Yutaka Kimura Akira Koike Masahiro Kohzuki Shinji Koba Masataka Sata Kazunori Shimada Tomoki Shimokawa Hirokazu Shiraishi Naokata Sumitomo Tetsuya Takahashi Tomoyuki Takura Hiroyuki Tsutsui Masatoshi Nagayama Emiko Hasegawa Yoshihiro Fukumoto Yutaka Furukawa Shin-ichiro Miura Satoshi Yasuda Sumio Yamada Yuichiro Yamada Dai Yumino Toshiko Yoshida Takuji Adachi Toshimi Ikegame Kazuhiro P Izawa Takeshi Ishida Neiko Ozasa Naohiko Osada Hiroaki Obata Naoya Kakutani Yusuke Kasahara Masaaki Kato Kentaro Kamiya Shintaro Kinugawa Yuji Kono Yasuyuki Kobayashi Teruyuki Koyama Kazuhiro Sase Shinji Sato Tatsuhiro Shibata Norio Suzuki Daisuke Tamaki Minako Yamaoka-Tojo Michio Nakanishi Eisaku Nakane Mari Nishizaki Taiki Higo Kanta Fujimi Tasuku Honda Yasuharu Matsumoto Noriko Matsumoto Ikuko Miyawaki Makoto Murata Shusuke Yagi Masanobu Yanase Midori Yamada Miho Yokoyama Noboru Watanabe Haruki Ito Takeshi Kimura Syunei Kyo Yoichi Goto Ryuji Nohara Ken-Ichi Hirata on behalf of the Japanese Circulation Society/the Japanese Association of Cardiac Rehabilitation Joint Working Group

出版者

The Japanese Circulation Society

雑誌

Circulation Journal (ISSN:13469843)

巻号頁・発行日

pp.CJ-22-0234, (Released:2022-12-09)

参考文献数

559

被引用文献数

64

著者

Yasunori Suematsu Shin-ichiro Miura Akira Minei Yoko Sumita Koshiro Kanaoka Michikazu Nakai Hisatomi Arima Koshi Nakamura Tomoyuki Takura Kazunori Shimada Hirokazu Shiraishi Nagaharu Fukuma Yusuke Ohya Shigeru Makita The JROAD-CR Investigators

出版者

The Japanese Circulation Society

雑誌

Circulation Reports (ISSN:24340790)

巻号頁・発行日

pp.CR-22-0121, (Released:2023-01-25)

参考文献数

15

---

Background: Although cardiac rehabilitation (CR) has been reported to be effective for improving the prognosis of acute myocardial infarction (AMI), more patients must participate in CR during admission and as outpatients. Factors contributing to, and countermeasures against, the low CR participation rate need to be identified. Here we describe the protocol for a study designed to evaluate the effectiveness and problems of CR for AMI from the Japanese Registry of All Cardiac and Vascular Diseases (JROAD) and the JROAD–Japanese Diagnosis Procedure Combination system (JROAD-DPC) database.Methods and Results: This is a multicenter retrospective cohort study that will use the JROAD/JROAD-DPC database to evaluate the effectiveness of CR for AMI (JROAD-CR). Five thousand patients with AMI who were admitted to hospitals registered in the JROAD database in 2014 will be investigated with regard to their baseline characteristics, AMI severity and treatment, examination results, history of CR, and prognosis up to 5 years. We will also investigate the presence, quantity, and quality of CR, and evaluate the effectiveness of CR with respect to cost, exercise tolerance, and prognosis during admission and follow-up.Conclusions: The JROAD-CR study will seek to reveal the effectiveness of CR for AMI in the era of early reperfusion therapy and shortened hospitalization.

著者

Gen Inoue Takashi Kaito Yukihiro Matsuyama Toshihiko Yamashita Mamoru Kawakami Kazuhisa Takahashi Munehito Yoshida Shiro Imagama Seiji Ohtori Toshihiko Taguchi Hirotaka Haro Hiroshi Taneichi Masashi Yamazaki Kotaro Nishida Hiroshi Yamada Daijiro Kabata Ayumi Shintani Motoki Iwasaki Manabu Ito Naohisa Miyakoshi Hideki Murakami Kazuo Yonenobu Tomoyuki Takura Joji Mochida

出版者

The Japanese Society for Spine Surgery and Related Research

雑誌

Spine Surgery and Related Research (ISSN:2432261X)

巻号頁・発行日

pp.2020-0083, (Released:2020-11-20)

被引用文献数

2

---

Introduction: Chronic low back pain (CLBP) is a leading cause of disability, yet there is limited high-quality evidence to identify the most suitable pharmacological therapy. The purpose of this Japanese nationwide, multicenter, prospective study was to compare the effectiveness of four representative drug therapies—acetaminophen, celecoxib, loxoprofen, and a tramadol and acetaminophen (T+A) combination drug—to establish evidence for a drug of choice for CLBP.Methods: Patients with CLBP (N = 471) received one of the four treatments and were evaluated, prospectively and comprehensively, once every month for six months using a visual analog scale (VAS) for LBP, the Japanese Orthopedic Association (JOA) score, the JOA Back Pain Evaluation Questionnaire (JOABPEQ), the Roland–Morris Disability Questionnaire (RDQ), the EuroQol five-dimensions three-levels (EQ-5D-3L), and the Short Form-8 item health survey (SF-8). We conducted multivariable linear regression analyses of the four drugs at 1 and 6 months after drug allocation. Differences with P < 0.05 were considered statistically significant.Results: Patients who received acetaminophen showed a significant improvement from baseline in the mental health subscale of the JOABPEQ at one month (P = 0.02) and the JOA score at six months (P < 0.01). None of the other outcome measures among the four drugs differed significantly. Across groups, all outcome measures, except the mental component summary (MCS) score of the SF-8, improved equivalently, although most measurements showed no obvious cumulative effect over six months. The MCS score of the SF-8 decreased gradually over six months in all groups.Conclusions: Most of the outcome measures among the treated groups were not significantly different, indicating similar treatment effects of the four drugs for CLBP. Our study indicated the limit of each outcome measure for evaluating the patient status, suggesting that a single outcome measure is insufficient to reflect treatment effectiveness.

著者

Satoshi Kodera Hiroyuki Morita Arihiro Kiyosue Jiro Ando Tomoyuki Takura Issei Komuro

出版者

The Japanese Circulation Society

雑誌

Circulation Journal (ISSN:13469843)

巻号頁・発行日

vol.82, no.10, pp.2602-2608, 2018-09-25 (Released:2018-09-25)

参考文献数

39

被引用文献数

2 12

---

Background: The addition of a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor to statin therapy reduces the rate of cardiovascular events. This study examined the cost-effectiveness of PCSK9 inhibitor+statin compared with standard therapy (statin monotherapy) in the treatment of triple-vessel coronary artery disease (CAD) in Japan. Methods and Results: A Markov model was applied to assess the costs and benefits associated with PCSK9 inhibitor+statin over a projected 30-year period from the perspective of a public healthcare payer in Japan. The incremental cost-effectiveness ratio (ICER), expressed as the quality-adjusted life-years (QALYs), was estimated. The effects on survival and numbers of events were based on the FOURIER trial and the CREDO Kyoto registry. The ICER of PCSK9 inhibitor+statin over standard therapy was 13.5 million (95% confidence interval 7.6–23.5 million) Japanese Yen (JPY) per QALY gained for triple-vessel CAD. The probability of the cost-effectiveness of PCSK9 inhibitor+statin vs. standard therapy was 0.0008% at a cost-effectiveness threshold of 5 million JPY. In patients with poorly controlled familial hypercholesterolemia (FH) with triple-vessel CAD, the ICER was 3.4 million JPY per QALY gained. Conclusions: PCSK9 inhibitor plus statin did not show good cost-effectiveness for triple-vessel CAD; however, it showed good cost-effectiveness for patients with triple-vessel CAD and poorly controlled FH in Japan.